After years of losses, London-listed Buccaneer Energy (LON:BUCE) is projected by analysts to turn its first profit in 2026, marking a potential turning point for the US-focused hydrocarbon explorer.
The UK government's £25m investment in Octopus Energy's Kraken Technologies through the British Business Bank raises critical questions about the use of taxpayer funds to back an already scaled, global, and recently loss-making platform.
After a brutal 2025, fast-casual restaurant stocks are rallying sharply in early 2026. Analysts debate whether this marks a genuine recovery or a temporary bounce, as consumers pivot towards grocery and convenience store meals, forcing a reckoning on value and quality.
While Morgan Stanley maintains an Overweight rating on PDD Holdings, the firm has removed the e-commerce giant from its Top Picks list, citing heightened regulatory scrutiny and a slower-than-expected consumer recovery in China.
ResMed reports robust revenue and margin expansion in its fiscal Q2 2026, driven by strong device and mask sales. Management highlights strategic investments in AI-powered patient tools and views GLP-1 medications as a potential catalyst for future demand.
Fastly's stock has surged on the coattails of broader AI and edge computing optimism, but a closer look reveals a complex picture of short-term gains against longer-term struggles. As the market weighs future growth against persistent losses, investors are left questioning if the recent rally has legs.
A sharp downturn in cryptocurrency markets has spilled over into the stocks of major corporate holders, with MicroStrategy and BitMine leading losses as their aggressive accumulation strategies face mounting pressure.
ResMed Inc. reports an 11% revenue surge for its second fiscal quarter, driven by robust mask sales and strategic acquisitions, while navigating competitive pressures and capitalizing on emerging healthcare trends.
A wave of risk aversion sweeps global markets, dragging cryptocurrencies down sharply. Bitcoin's technical breakdown and a steep drop for Worldcoin highlight a day of heavy losses and liquidations.
Shares of communications testing firm Viavi Solutions surged over 17% to a level not seen since 2002, as investors cheered a new restructuring initiative aimed at saving $30 million annually, despite the company posting a quarterly net loss.
LendingClub Corp. (LC) shares tumbled sharply this week, extending losses for a third consecutive session after the company announced a shift to fair value accounting. The move, aimed at aligning revenue with credit costs, spooked investors despite the fintech firm reporting a 164% surge in annual net income.
PUMA SE (XTRA:PUM) presents a complex picture for investors. While recent quarterly momentum has lifted shares, a deep dive reveals persistent losses and multi-year underperformance, raising questions about its true valuation and path to sustained profitability.
After years of lackluster performance, Digistar Corporation Berhad (KLSE:DIGISTA) is showing early signs of a operational turnaround, marked by a notable improvement in its return on capital employed. While still trailing the industry average, the shift from losses to profitability on a reduced capital base offers a glimmer of hope for the battered stock.
Klarna Group confronts a wave of class action lawsuits alleging it downplayed rising loan loss risks in its buy-now-pay-later portfolio ahead of its 2025 NYSE debut. The legal challenges cast a shadow over the fintech's post-IPO performance and have sparked a broader debate about transparency in the rapidly growing BNPL sector.
Amgen has terminated its collaboration with Kyowa Kirin on the atopic dermatitis drug rocatinlimab, handing full development rights back to the Japanese partner. The strategic shift comes as Amgen's stock trades above most fair value estimates, raising questions about its current valuation amid pipeline recalibration.
Nurix Therapeutics, a clinical-stage biopharma company, is gaining attention for its novel protein degradation platform. With strong early data for its lead drug, key regulatory designations, and strategic partnerships with industry giants, the company is positioning itself to address unmet needs in multi-billion dollar oncology markets.
Investor and TV personality Kevin O'Leary has thrown his weight behind a proposed national child investment account policy, framing it as a bipartisan solution to America's widespread financial illiteracy and a foundational tool for building generational wealth.
As Archer Aviation advances toward FAA certification for its Midnight air taxi, bullish investors point to its strong liquidity and strategic partnerships. But with the company still pre-revenue and burning cash, the path to commercial launch by 2026 remains a high-stakes race against time and regulation.
The swearing-in of Rep. Christian Menefee (D-Texas) on Monday tightens the House margin to 218-214, leaving Speaker Mike Johnson with virtually no room for error on key votes, starting with this week's critical government funding bill.
Amid a challenging market for biotech, C4 Therapeutics (NASDAQ: CCCC) is drawing investor attention with its targeted protein degradation platform. Backed by industry giants and focused on niche cancers, the clinical-stage company presents a high-risk, high-reward proposition. We examine the bull case and the road ahead.
